ADVM: Rasio kapitalisasi marang pendapatan Adverum Biotechnologies

The field of vision gene therapy ensures high patient loyalty thanks to the drug Ixo-vec, although geopolitical conflicts and sanctions restrict logistics and access to global markets. Effective management at Adverum Biotechnologies (ADVM) has optimized expenses while maintaining liquidity. The P/S market multiple on this chart demonstrates the company's sales valuation, with the value stabilizing at 90.80.

The innovative Ixo-vec vector allows Adverum Biotechnologies (ADVM) to radically reduce the frequency of injections for AMD, creating high added value. The price-to-sales ratio reflects how much an investor is willing to pay for every dollar of the company's actual sales. This coefficient compares market capitalization with annual turnover, revealing the extent to which the business is overvalued or undervalued. Analyzing this ratio helps determine the risk of capital losses during a shift in the market cycle.